CO2023001489A2 - Proceso de fraccionamiento de plasma usando plasma humano secado por atomización - Google Patents

Proceso de fraccionamiento de plasma usando plasma humano secado por atomización

Info

Publication number
CO2023001489A2
CO2023001489A2 CONC2023/0001489A CO2023001489A CO2023001489A2 CO 2023001489 A2 CO2023001489 A2 CO 2023001489A2 CO 2023001489 A CO2023001489 A CO 2023001489A CO 2023001489 A2 CO2023001489 A2 CO 2023001489A2
Authority
CO
Colombia
Prior art keywords
plasma
spray
dried human
human plasma
fractionation process
Prior art date
Application number
CONC2023/0001489A
Other languages
English (en)
Inventor
Zhorzh Patatanyan
Rohit Murthy
Yasser Baddour
Alexander Zaydenberg
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CO2023001489A2 publication Critical patent/CO2023001489A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/145—Extraction; Separation; Purification by extraction or solubilisation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D1/00—Evaporating
    • B01D1/16—Evaporating by spraying
    • B01D1/18—Evaporating by spraying to obtain dry solids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D1/00—Evaporating
    • B01D1/14—Evaporating with heated gases or vapours or liquids in contact with the liquid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8128—Antithrombin III

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención proporciona un método de fraccionamiento de plasma humano, en algunas modalidades, usando el procedimiento de fraccionamiento de Cohn. La mejora comprende el uso de plasma humano secado por atomización reconstituido fisiológicamente activo como el material de partida para el procedimiento de fraccionamiento.
CONC2023/0001489A 2020-10-01 2023-02-10 Proceso de fraccionamiento de plasma usando plasma humano secado por atomización CO2023001489A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063086335P 2020-10-01 2020-10-01
PCT/IB2021/000680 WO2022069945A1 (en) 2020-10-01 2021-10-01 Plasma fractionation process utilizing spray-dried human plasma

Publications (1)

Publication Number Publication Date
CO2023001489A2 true CO2023001489A2 (es) 2023-02-16

Family

ID=79170928

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0001489A CO2023001489A2 (es) 2020-10-01 2023-02-10 Proceso de fraccionamiento de plasma usando plasma humano secado por atomización

Country Status (12)

Country Link
US (1) US20220106357A1 (es)
EP (1) EP4222161A1 (es)
JP (1) JP2023545948A (es)
KR (1) KR20230078629A (es)
CN (1) CN116096385A (es)
AU (1) AU2021354979A1 (es)
BR (1) BR112023003010A2 (es)
CA (1) CA3189976A1 (es)
CO (1) CO2023001489A2 (es)
IL (1) IL300384A (es)
MX (1) MX2023003483A (es)
WO (1) WO2022069945A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9561184B2 (en) 2014-09-19 2017-02-07 Velico Medical, Inc. Methods and systems for multi-stage drying of plasma
US11998861B2 (en) 2022-09-15 2024-06-04 Velico Medical, Inc. Usability of a disposable for a spray drying plasma system
US11975274B2 (en) 2022-09-15 2024-05-07 Velico Medical, Inc. Blood plasma product
US11841189B1 (en) * 2022-09-15 2023-12-12 Velico Medical, Inc. Disposable for a spray drying system

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8407912B2 (en) * 2010-09-16 2013-04-02 Velico Medical, Inc. Spray dried human plasma
AU2010202125B1 (en) * 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
US20140083627A1 (en) * 2012-09-27 2014-03-27 Velico Medical, Inc. Automated spray drier

Also Published As

Publication number Publication date
IL300384A (en) 2023-04-01
WO2022069945A1 (en) 2022-04-07
AU2021354979A1 (en) 2023-02-23
BR112023003010A2 (pt) 2023-04-04
KR20230078629A (ko) 2023-06-02
CN116096385A (zh) 2023-05-09
MX2023003483A (es) 2023-04-14
EP4222161A1 (en) 2023-08-09
JP2023545948A (ja) 2023-11-01
US20220106357A1 (en) 2022-04-07
CA3189976A1 (en) 2022-04-07

Similar Documents

Publication Publication Date Title
CO2023001489A2 (es) Proceso de fraccionamiento de plasma usando plasma humano secado por atomización
CL2021000415A1 (es) Vesículas derivadas de lactobacillus paracasei y uso de las mismas
MX2021013581A (es) Composiciones de nanoemulsiones que comprenden ingredientes biologicamente activos.
GT201300174A (es) Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme)
AR083561A1 (es) Preparacion de una construccion antigenica
CR20120490A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
EA201790889A1 (ru) Офтальмологический раствор
CL2011003003A1 (es) Composicion tensioactiva reconstituida que comprende un polipeptido análogo a la proteína surfactante c nativa, un polipeptido análogo a la proteína surfactante b nativa, un fosfolipido monoinsaturado y un fosfolipido saturado, útil para el tratamiento del síndrome de dificultad respiratoria.
MX2020004712A (es) Vesiculas extracelulares modificadas geneticamente con proteinas.
ECSP10010372A (es) Métodos y composiciones que utilizan polipéptidos de fusión de klotho-fgf
CL2019000485A1 (es) Uso de pridopidina para el tratamiento de la disminución funcional.
PE20190907A1 (es) Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas
UY33017A (es) Tratamiento para trastornos gastrointestinales
CL2015002835A1 (es) Nuevos derivados de piridina
EA201491155A1 (ru) Новые мутантные про-нрф и их применение для получения бета-нрф
AU2017267370A1 (en) A method to enhance wound healing using silk-derived protein
MX2022006807A (es) Análogos de rapamicina y usos de estos.
EA202091095A1 (ru) Пероральная доставка пептидных аналогов glp-1
CO2020004407A2 (es) Formulaciones de espora de nutriente y usos de las mismas
CO6592047A2 (es) Formulación tópica oftálmica de péptidos
AR086207A1 (es) Composiciones y metodos
AR126239A1 (es) Región 5’ no traducida y región 3’ no traducida no naturales y uso de estas
CL2019002145A1 (es) Composición farmacéutica que comprende betahistina.
UY36815A (es) PROCEDIMIENTO PARA EL TRATAMIENTO DE ENFERMEDADES INFECCIOSAS UTILIZANDO UNA COMPOSICION QUE COMPRENDE INMUNOGLOBULINA M (IgM) DERIVADA DE PLASMA
BR112019004639A2 (pt) formulações de 4-metil-5-(pirazin-2-il)-3h-1,2-ditiol-3-tiona, formulações de gosto modificado e métodos para produzir e usar as mesmas